The role of mTOR inhibitors for treatment of sarcomas.
Bone and soft tissue sarcomas represent rare tumors that can be cured by local treatment at early stages of disease. However, advanced or metastatic disease is rarely cured, and very few drugs have shown efficacy in this setting. Early studies with mTOR inhibitors have demonstrated antitumor activity in patients with metastatic sarcoma who failed previous chemotherapies. The response rate and durable stable disease in early studies, as well as the tolerability profile, recommend these drugs as promising candidates for further clinical studies. This article discusses preliminary results from clinical trials in patients with advanced or metastatic sarcoma as well as future perspectives.
Mita
Monica M
MM
Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78230, USA. mmita@idd.org
Tolcher
Anthony W
AW
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary; D004359:Drug Therapy, Combination; D000068338:Everolimus; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy; D006801:Humans; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011494:Protein Kinases / Q000502:physiology*; D012509:Sarcoma / Q000188:drug therapy* / Q000556:secondary; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D012983:Soft Tissue Neoplasms / Q000188:drug therapy* / Q000556:secondary; D058570:TOR Serine-Threonine Kinases
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; C515074:ridaforolimus; C401859:temsirolimus; D000068338:Everolimus; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus